Drugs / DP-R212
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02814500 | Jul → Sep 2016 | — | Alvogen Korea | Unknown | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT02955368 | Feb → Jul 2017 | hyperlipoproteinemia, hypertensive disorder | Alvogen Korea | Withdrawn | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DP-R212 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02814500 ↗ |